… Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement provides ProQR with … divest its late stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR …
… Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Divestment of sepofarsen and … divesting late stage ophthalmic assets, sepofarsen and ultevursen, to Laboratoires Théa (Théa). “Following previous …
ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
… ProQR agreement with Laboratoires Théa for sepofarsen and ultevursen inherited retinal disease programs . Strategic … readout of the modified Phase 2/3 Sirius trial of ultevursen. For a full update, please read our community …
The EFF Spring Virtual Summit hosted by ProQR on April 15 is a virtual meeting featuring the latest clinical data for USH2A mediated Usher syndrome and retinitis pigmentosa and a live panel discussion.
ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
